Medicare Enrolled
Dr. Ajay Sehgal, MD
Hematology & Oncology · Corpus Christi, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Sehgal from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sehgal?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Sehgal
Dr. Ajay Sehgal is a hematology & oncology specialist in Corpus Christi, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Sehgal performed 101,610 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Sehgal received a total of $14,123 from 69 pharmaceutical and/or device companies across 641 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sehgal is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years of NPI registration
▲ Top 7% volume in TX
$14,123 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗101,610
Medicare services
Top 7% in TX for hematology & oncology
Not available
Unique patients (not deduplicated)
$16
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Nivolumab injection (Opdivo) | 48,720 | $24 | $45 |
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
18,870 | $0 | $2 |
| Anti-nausea injection (ondansetron/Zofran) | 10,948 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 7,920 | $18 | $30 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
7,839 | $0 | $0 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
1,780 | $21 | $60 |
| Pegfilgrastim-cbqv injection An injection of pegfilgrastim-cbqv, a biosimilar medication, administered at a dose of 0.5 mg. |
888 | $107 | $400 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
852 | $95 | $275 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
663 | $1 | $2 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
452 | $10 | $40 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
355 | $91 | $160 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
347 | $2 | $5 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
302 | $47 | $135 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
276 | $0 | $15 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
232 | $20 | $60 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
151 | $127 | $300 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
118 | $87 | $200 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
116 | $10 | $30 |
| New patient office visit, complex (60-74 min) | 109 | $154 | $400 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
104 | $7 | $20 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
90 | $60 | $150 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
88 | $53 | $150 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
75 | $91 | $190 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
74 | $17 | $50 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
64 | $46 | $140 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
55 | $17 | $50 |
| Prolonged intravenous chemotherapy administration This procedure involves the administration of chemotherapy medication directly into a vein over an extended period. |
48 | $88 | $300 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
42 | $42 | $85 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
18 | $12 | $50 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
14 | $64 | $160 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
21.5% high complexity
77.1% medium
1.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$14,123
Total received (2018-2024)
Avg $2,018/year across 7 years
Top 25% in TX for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
69
Companies
641
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,285
2023
$2,719
2022
$2,487
2021
$1,872
2020
$580
2019
$1,044
2018
$1,137
Payments by company (2024)
Novartis Pharmaceuticals Corporation
$1,415
E.R. Squibb & Sons, L.L.C.
$378
Merck Sharp & Dohme LLC
$309
AstraZeneca Pharmaceuticals LP
$240
Janssen Biotech, Inc.
$173
Stryker Corporation
$170
PFIZER INC.
$166
Astellas Pharma US Inc
$163
TAIHO ONCOLOGY, INC.
$119
Ipsen Biopharmaceuticals, Inc
$115
Genentech USA, Inc.
$115
Takeda Pharmaceuticals U.S.A., Inc.
$101
Celgene Corporation
$96
Daiichi Sankyo Inc.
$77
Eisai Inc.
$76
ABBVIE INC.
$72
GlaxoSmithKline, LLC.
$57
Gilead Sciences, Inc.
$53
Karyopharm Therapeutics Inc.
$49
Exelixis Inc.
$49
BeiGene USA, Inc.
$38
GENZYME CORPORATION
$37
ADC Therapeutics America, Inc.
$31
Alexion Pharmaceuticals, Inc.
$30
Organon Llc
$28
Janssen Pharmaceuticals, Inc
$22
Tempus AI, Inc
$20
ARRAY BIOPHARMA INC
$20
Lilly USA, LLC
$19
Stemline Therapeutics Inc.
$16
Mirati Therapeutics, Inc.
$16
SpringWorks Therapeutics, Inc.
$15
Top 3 companies account for 49.0% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$2,488
E.R. Squibb & Sons, L.L.C.
$1,505
PFIZER INC.
$813
AstraZeneca Pharmaceuticals LP
$766
Merck Sharp & Dohme LLC
$658
Janssen Biotech, Inc.
$572
Celgene Corporation
$406
Lilly USA, LLC
$365
Karyopharm Therapeutics Inc.
$364
Gilead Sciences, Inc.
$288
Incyte Corporation
$286
Takeda Pharmaceuticals U.S.A., Inc.
$271
Genentech USA, Inc.
$257
Daiichi Sankyo Inc.
$237
Kite Pharma, Inc.
$231
GlaxoSmithKline, LLC.
$227
Eisai Inc.
$221
Astellas Pharma US Inc
$220
ADC Therapeutics America, Inc.
$210
Seagen Inc.
$204
GENZYME CORPORATION
$201
AVEO Pharmaceuticals, Inc.
$180
Stryker Corporation
$170
TAIHO ONCOLOGY, INC.
$168
Regeneron Healthcare Solutions, Inc.
$164
Merck Sharp & Dohme Corporation
$158
COMSORT, Inc
$150
BeiGene USA, Inc.
$138
Exelixis Inc.
$134
ARRAY BIOPHARMA INC
$133
Ipsen Biopharmaceuticals, Inc
$131
Melinta Therapeutics, LLC
$130
Mirati Therapeutics, Inc.
$119
Puma Biotechnology, Inc.
$117
Janssen Scientific Affairs, LLC
$105
Nevro Corp.
$83
MorphoSys, US Inc.
$81
Pharmacyclics LLC, An AbbVie Company
$76
ABBVIE INC.
$72
SOBI, INC
$70
Boehringer Ingelheim Pharmaceuticals, Inc.
$64
Pharmacyclics LLC, an AbbVie Company
$58
AbbVie, Inc.
$52
Clovis Oncology, Inc.
$52
EISAI INC.
$52
EMD Serono, Inc.
$48
Dova Pharmaceuticals
$44
Coherus Biosciences Inc.
$38
Myovant Sciences Inc.
$38
AbbVie Inc.
$37
Sobi, Inc
$35
PUMA BIOTECHNOLOGY, INC.
$31
Stemline Therapeutics Inc.
$31
Bayer Healthcare Pharmaceuticals Inc.
$30
Alexion Pharmaceuticals, Inc.
$30
Sandoz Inc.
$29
SECURA BIO, INC.
$29
Epizyme, Inc.,
$28
Organon Llc
$28
Mylan Institutional Inc.
$28
TESARO, Inc.
$23
Janssen Pharmaceuticals, Inc
$22
Tempus AI, Inc
$20
ImmunoGen, Inc.
$20
Bayer HealthCare Pharmaceuticals Inc.
$19
Rigel Pharmaceuticals, Inc.
$19
Blueprint Medicines Corporation
$18
Taiho Oncology, Inc.
$18
SpringWorks Therapeutics, Inc.
$15
Top 3 companies account for 34.0% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · Abraxane · Alecensa · BAVENCIO · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · CABLIVI · CABOMETYX · CALQUENCE · COPIKTRA · COSELA · CYRAMZA · Cabometyx · Columvi · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELITEK · EMPLICITI · ENHERTU · EPKINLY · ERLEADA · Elahere · Enhertu · Erleada · FOTIVDA · FRUZAQLA · Fabhalta · GAVRETO · GILOTRIF · Gazyva · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · Inrebic · JADENU · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kimyrsa · LIBTAYO · LONSURF · LORBRENA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Nubeqa · OGIVRI · OGSIVEO · OJJAARA · ONTRUZANT · OPDIVO · OPDUALAG · ORGOVYX · Ogivri · Omnia · Onivyde · Orserdu · PADCEV · PIQRAY · PROMACTA · Padcev · Phesgo · Pomalyst · REBLOZYL · RETEVMO · RYBREVANT · RYDAPT · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SHINGRIX · SPY-PHI SYSTEM · SUTENT · Somatuline Depot · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIVDAK · TUKYSA · Tavalisse · Tecentriq · Tecentriq Hybreza · Trodelvy · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · VOTRIENT · Venclexta · XALKORI · XPOVIO · XTANDI · Xospata · Xtandi · Yescarta · ZARXIO · ZEJULA · ZIEXTENZO · ZYTIGA
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
4
County median income
$66,021
Nearest hospital to ZIP centroid (approximate)
CORPUS CHRISTI MEDICAL CENTER,THE
3.0 mi
3.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Sehgal is a mixed practice specialist, with above-average Medicare volume (top 7% in TX), with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Sehgal experienced with nivolumab injection (opdivo)?
Based on Medicare claims data, Dr. Sehgal performed 48,720 nivolumab injection (opdivo) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Sehgal receive payments from pharmaceutical companies?
Yes. Dr. Sehgal received a total of $14,123 from 69 companies across 641 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sehgal's costs compare to other hematology & oncology specialists in Corpus Christi?
Dr. Sehgal's average Medicare payment per service is $16. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sehgal) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Corpus Christi
Browse hematology & oncology specialists in Corpus Christi ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in TX
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in TX
Which TX hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology